AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2022
Sep 12, 2022
32312_dirs_2022-09-12_f3c0a2f2-255f-4ed6-844d-1e0fcb11bd87.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-09-08
Reporting Person: WEN LEANA (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-09-08 | Stock Option (right to buy) | $7.73 | A | 20000 | Acquired | 2032-09-08 | Ordinary Shares (20000) | Direct |
Footnotes
F1: The shares underlying the stock option vest in equal quarterly installments for 12 quarters
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11